The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cumberland Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $9.13 Mil. Cumberland Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $15.60 Mil.
Hence, Cumberland Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.59.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cumberland Pharmaceuticals Receivables Turnover Related Terms
Cumberland Pharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPIX vs INCR, CTOR, TLPH: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cumberland Pharmaceuticals (CPIX) has a Receivables Turnover of 0.59 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cumberland Pharmaceuticals and its competitors. According to the industry distribution chart, Cumberland Pharmaceuticals ranks #729 out of 944 companies in the Drug Manufacturers industry, placing it in the top 77.2%.
Is Cumberland Pharmaceuticals' Receivables Turnover too high?
Cumberland Pharmaceuticals' current Receivables Turnover is 0.59. The Drug Manufacturers industry median Receivables Turnover is 5.07. Cumberland Pharmaceuticals' value of 0.59 is 88.4% below this industry median. Based on the distribution chart, Cumberland Pharmaceuticals ranks #729 out of 944 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cumberland Pharmaceuticals has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' Receivables Turnover compare to INCR and CTOR?
According to the Drug Manufacturers industry distribution chart, Cumberland Pharmaceuticals ranks #729 out of 944 companies for Receivables Turnover. This places Cumberland Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.07. Cumberland Pharmaceuticals' value of 0.59 is 88.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cumberland Pharmaceuticals's current Receivables Turnover of 0.59 is 88.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cumberland Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cumberland Pharmaceuticals's current Receivables Turnover is 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $6.43 — trading 197.7% above its estimated fair value. The current Receivables Turnover is 0.59 and 88.4% below the Drug Manufacturers industry median of 5.07. Cumberland Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current Receivables Turnover is 0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued.
The current stock price of $6.43 is trading 197.7% above its estimated GF Value™ of $2.16.
GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CPIX:
Receivables Turnover: 0.59
GF Value™: $2.16 vs. price of $6.43 (197.7% above fair value)
Industry Position: 88.4% below the Drug Manufacturers median (#729 of 944)
No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
36GF Score
Get the complete analysis for CPIX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPIX has been successfully added to your 
